Christine Zedelmayer Sells 14,584 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 14,584 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $2.93, for a total value of $42,731.12. Following the completion of the sale, the chief operating officer directly owned 62,586 shares in the company, valued at approximately $183,376.98. The trade was a 18.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The shares were sold at an average price of $2.80, for a total value of $240,833.60.
• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The shares were sold at an average price of $2.70, for a total value of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The shares were sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Stock Performance

Shares of NASDAQ:EQ traded down $0.23 during trading on Friday, hitting $2.94. The company’s stock had a trading volume of 1,143,183 shares, compared to its average volume of 595,254. The business has a 50 day moving average price of $2.18 and a two-hundred day moving average price of $1.70. The company has a market capitalization of $185.89 million, a PE ratio of -9.19 and a beta of 1.77. Equillium, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $3.45.

Equillium (NASDAQ:EQ) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). As a group, equities analysts expect that Equillium, Inc. will post -0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Equillium

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in Equillium by 10.8% in the first quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company’s stock valued at $12,957,000 after acquiring an additional 632,359 shares during the last quarter. Eversept Partners LP purchased a new stake in Equillium in the first quarter valued at $2,998,000. OMERS ADMINISTRATION Corp purchased a new stake in Equillium in the first quarter valued at $100,000. Affinity Asset Advisors LLC purchased a new stake in Equillium in the first quarter valued at $2,453,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Equillium in the first quarter valued at $31,000. 27.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on EQ shares. Cantor Fitzgerald started coverage on shares of Equillium in a research note on Tuesday, April 7th. They issued an “overweight” rating and a $10.00 price target for the company. Leerink Partners upgraded shares of Equillium from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $1.00 to $6.00 in a research note on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a research note on Friday, March 27th. Zacks Research upgraded shares of Equillium to a “hold” rating in a research note on Thursday, February 26th. Finally, B. Riley Financial began coverage on shares of Equillium in a research note on Thursday, April 16th. They set a “buy” rating and a $6.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Equillium has an average rating of “Moderate Buy” and an average target price of $7.57.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.